Predicting Factors Associated with Hypoglycemia Reduction with Automated Predictive Insulin Suspension in Patients at High Risk of Severe Hypoglycemia: An Analysis from the SMILE Randomized Trial

Aklilu Habteab, PhD,1 Javier Castañeda, MS,1 Harold de Valk, MD, PhD,2 Pratik Choudhary, MBBS, MD, FRCP,3 Emanuele Bosi, MD,4 Sandrine Lablanche, MD,5 Simona de Portu, PharmD, MS,6 Julien Da Silva, MS,6 Linda Vorrink-de Groot, MS,6 John Shin, PhD, MBA,7 and Ohad Cohen, MD6

Abstract

Background: This analysis from the SMILE randomized study was performed to identify predictive factors associated with the greatest reductions in hypoglycemia with the Medtronic MiniMed™ 640G Suspend before low feature in adults with type 1 diabetes at high risk of severe hypoglycemia.

Methods: Clinical and treatment-related factors associated with decreased sensor hypoglycemia (SH) were identified in participants from the intervention arm by univariate and multivariate analyses.

Results: The reduction in SH events <54 mg/dL (<3.0 mmol/L) in the intervention group was significantly (P < 0.0001) associated with the baseline mean number of sensor hypoglycemic events (MNSHE) <54 mg/dL. When excluding continuous glucose monitoring (CGM) factors not readily available (MNSHE, duration of SH events, area under the curve, mean amplitude of glycemic excursions), only the baseline mean time spent <54 mg/dL was found to be a significant independent predictor factor (P < 0.0001). Baseline HbA1c, mean self-monitoring of blood glucose (SMBG), and coefficient of variation of SMBG were significant, although weak, predictors in the absence of any CGM data.

Conclusions: The greatest reductions in SH events achieved with the MiniMed 640G system with the Suspend before low feature were seen in participants with higher baseline MNSHE. Measuring these (usually uncollected) events can be a useful tool to predict hypoglycemia reduction. ClinicalTrials.gov Registration Identifier NCT02733991.

Keywords: Diabetes mellitus, Type 1, Hypoglycemia, Insulin infusion systems, Severe hypoglycemia, Predictive low glucose management.

1Medtronic Bakken Research Center, Maastricht, The Netherlands.
2Department of Internal Medicine, University Medical Center, Utrecht, The Netherlands.
3Department of Internal Medicine King’s College Hospital, Diabetes Research Group, London, United Kingdom.
4Diabetes Research Institute, IRCCS San Raffaele Hospital and San Raffaele Vita Salute University, Milano, Italy.
5Department of Diabetology, Grenoble University Hospital, Service d’Endocrinologie, Grenoble, France.
6Medtronic International Trading Sarl, Tolochenaz, Switzerland.
7Medtronic, Northridge, California, USA.
Introduction

Attempts to achieve optimal glycemia often incur an increased risk of severe hypoglycemia.1-3 Risk factors for severe hypoglycemia include duration of diabetes, previous severe hypoglycemic events, and hypoglycemia unawareness, which are present in ~20% of people with type 1 diabetes.4-5 The recent SMILE (Study of MiniMed 640G insulin pump with Smart Guard in prevention of low glucose events in adults with type 1 diabetes) study6,7 showed that the use of the Medtronic MiniMedTM 640G insulin pump system with continuous glucose monitoring (CGM) and automated predictive low glucose management (PLGM) reduced hypoglycemic episodes (defined as sensor glucose <55 mg/dL [3.1 mmol/L] lasting ≥20 consecutive minutes) by 73%, and severe hypoglycemic episodes by 83.3%, in adults with type 1 diabetes at high risk of severe hypoglycemia.

This further analysis of the SMILE study data examined the association between the reduction in hypoglycemic episodes during the study and baseline characteristics in participants in the intervention arm, to identify factors predictive of greater reductions in hypoglycemia, and hence those individuals most likely to benefit from PLGM suspend before low functionality.

Materials and Methods

The methods of the SMILE study have been previously described.6,7 Briefly, this was a 6-month randomized controlled trial involving 169 participants aged 24–75 years with a ≥10-year duration of type 1 diabetes. After a 2-week run-in phase with blinded CGM, participants who successfully completed this phase were randomized to either the MiniMed 640G system (Medtronic, Northridge, CA, USA) with CGM and the SmartGuardTM PLGM suspend before low feature continuously turned on (intervention), or the MiniMed 640G pump without CGM (control), for 24 weeks.

Statistical analyses

Data from participants in the intervention arm were used to assess the association between baseline demographic and clinical factors and the reduction in mean number of sensor hypoglycemic events (MNSHE) during the study phase. The baseline demographic and clinical factors listed in Supplementary Table S2 were identified as clinically relevant, and they were considered for analysis. A sensor hypoglycemic event was defined as a sensor glucose <55 mg/dL for ≥20 consecutive minutes. Two-week CGM data collected during the run-in and on three occasions beginning at weeks 10, 16, and 22 of the study phase (period 1, 2, and 3, respectively) were used. The MNSHE during the study phase was calculated as the mean of the three periods, and the reduction in MNSHE was calculated as the change from baseline to study phase. For all CGM factors, data were considered to be missing in any period when sensor data were available for less than 3 days; no imputation of missing data was performed.

Statistical analysis of associations between baseline factors and reductions in hypoglycemia consisted of univariate analysis followed by multivariate analysis.

Univariate analysis with MNSHE change as response variable was first conducted for each variable separately: Factors with P-values <0.2 were retained for further analysis, and correlations between these factors were assessed by using Pearson correlation. Although the Pearson correlation was >0.7 or <0.7, only the factor with the smallest P-value in univariate analysis was included in the multivariate analysis, to avoid multicollinearity.

Three multivariate analyses were performed. Model 1 (the primary analysis) considered all baseline demographic, CGM, and clinical factors; Model 2 excluded CGM factors that are not readily available with current commercial CGM systems (MNSHE, duration of sensor hypoglycemia event, area under the curve, and MAGE); and Model 3 excluded all CGM-related factors, to identify factors predictive of hypoglycemia reduction in individuals not using real-time CGM.

For each of these models, a saturated model was used initially, including all the potential predictive factors identified in univariate analysis, and the final model was selected by manual backward selection; the most insignificant variables were eliminated one at a time until a parsimonious model with significant factors (P < 0.05) was identified.

Because the selected model included only participants in the intervention arm of the study, a sensitivity analysis including all randomized participants was performed by using the final model, with interaction with study arm (intervention or control) as a factor. Significance of the interaction in this sensitivity analysis was taken as confirmation that significance in the primary analysis was not due solely to a possible Hawthorne effect (i.e., the results were not attributable to study participation per se).

Results

The baseline characteristics of subjects randomized to the MiniMed 640G system with suspend before low feature have been previously published.7 The present analysis included 70 participants from the intervention arm: 6 participants in this arm had fewer than 3 days of CGM data at baseline, and they were excluded from this analysis. The baseline characteristics of the included participants were comparable to the entire study population in the intervention arm (n = 76) (Supplementary Table S1).

Supplementary Table S2 lists the factors that were significantly (P < 0.2) associated with reductions in MNSHE <54 mg/dL in univariate analysis. The final multivariate models are shown in Table 1.

In model 1, baseline MNSHE <54 mg/dL was the only baseline factor found to be significantly (P < 0.0001) associated with a reduction of MNSHE < 54 mg/dL. The model mean reduction of MNSHE = 0.2271 – 0.7937 × (baseline MNSHE) explained 91.3% of all variability. Participants with higher MNSHE at baseline showed larger reductions in MNSHE (Fig. 1); in a participant with a baseline MNSHE of 4, MNSHE would be reduced on average to 1.05 (73.7% reduction in sensor hypoglycemic events) (see Supplementary Table S3 for different baselines). Analysis for events based on 60 and 70 mg/dL was also performed as a sensitivity analysis, with similar results (Supplementary Table S4). Baseline MNSHE >60 and <70 mg/dL were the only significant factors associated with the reduction of MNSHE < 60 mg/dL (P < 0.0001, $R^2 = 83.9\%$) and <70 mg/dL (P < 0.0001, $R^2 = 71.2\%$).

In model 2, baseline time spent below 54 mg/dL was the only significant factor (P < 0.0001) and 85.1% of the variability was explained by the model, mean reduction of MNSHE = 0.0862 – 0.0565 × (baseline time spent below 54 mg/dL).
Participants who spent more time below 54 mg/dL at baseline experienced greater reductions in MNSHE (Supplementary Fig. S1): Each 10 min/day spent below this threshold at baseline was associated with an additional reduction in MNSHE of 0.57.

In model 3, baseline mean SMBG, coefficient of variation (CV) of SMBG, and HbA1c were significant, but this model \[\text{mean reduction of MNSHE} = -6.9297 + 0.6826 \times (\text{baseline HbA1c}) + 0.0341 \times (\text{baseline mean SMBG}) - 13.5020 \times (\text{baseline CV of SMBG})\] explained only 38.7% of all variability.

When an interaction between study arm and baseline MNSHE was included in Model 1 and fitted to data from all randomized participants, the interaction term was significant (estimate = 0.3848, \(P = 0.0007\)): A larger reduction in MNSHE was seen in the intervention arm than in the control arm (Supplementary Fig. S2). This confirms that the significant results seen in the primary analysis are not attributable to a study effect.

### Discussion

The analysis reported here extends the findings of the SMILE study, showing that baseline MNSHE is the strongest predictor of reductions in MNSHE: each additional MNSHE < 54 mg/dL at baseline was associated with an additional 0.8 reduction in MNSHE. This measure consistently predicted reduction in hypoglycemia events, irrespective of the MNSHE threshold (70, 60 or 54 mg/dL). However, the 54 mg/dL threshold demonstrated the highest attributable prediction \(R^2 = 0.913\), showing that PLGM provides the most robust protection from hypoglycemia in the most severe situation.

The finding that the extent of hypoglycemia reduction induced by technological interventions is a function of the baseline prevalence of hypoglycemia is not new: A 2008 meta-analysis of 22 studies in people with type 1 diabetes

---

**Table 1. Final Multivariate Models of the Association of Baseline Factors and Reduction of Mean Number of Sensor Hypoglycemic Event Per Week in Participants Using the MiniMed 640G with Suspend Before Low Feature Turned On**

| Regression coefficient | Standard error | P       |
|------------------------|---------------|---------|
| Model 1 (primary analysis): all baseline demographic and clinical factors included | | |
| Baseline MNSHE | -0.7937 | 0.029 | <0.0001 |
| Model 2: CGM factors that are not readily available with current commercial CGM systems excluded | | |
| Baseline time (minutes) spent < 54 mg/dL | -0.0565 | 0.002 | <0.0001 |
| Model 3: all CGM-related factors excluded | | |
| Baseline HbA1c | 0.6826 | 0.33 | 0.04 |
| Baseline mean SMBG | 0.0341 | 0.01 | 0.002 |
| Baseline coefficient of variation of SMBG | -13.5020 | 3.57 | 0.0003 |

*MNSHE, duration of MNSHE, AUC, and MAGE. AUC, area under the concentration-time curve; CGM, continuous glucose monitoring; MAGE, mean amplitude of glycemic excursions; MNSHE, mean number of sensor hypoglycemic events; SMBG, self-monitoring of blood glucose.*

Participants who spent more time below 54 mg/dL at baseline experienced greater reductions in MNSHE (Supplementary Fig. S1): Each 10 min/day spent below this threshold at baseline was associated with an additional reduction in MNSHE of 0.57.

---

**FIG. 1.** Change in MNSHE per week by baseline MNSHE per week. Solid line: regression line based on Model 1. Shaded area: 95% confidence interval for the regression line. Dotted lines: upper and lower limit of the 95% prediction interval. MNSHE, mean number of sensor hypoglycemic event.
found that the greatest reductions in hypoglycemia achieved with continuous subcutaneous insulin infusion were seen in individuals with the highest rates of severe hypoglycemia on multiple daily injections. Rather, the novelty of the present finding lies in the magnitude of the effect, and the fact that it remained independent and significant in multivariate analysis; whereas other factors associated with hypoglycemia in univariate analysis, such as insulin dose, age and duration of diabetes, HbA1c, mean sensor glucose, and other CGM measures, lost significance when modeled with baseline MNSHE. The phenomenon of regression to the mean in MNSHE can be seen in the control arm: There was no overall change in MNSHE from baseline to study phase, but participants with higher or lower baseline MNSHE showed reductions or increases in MNSHE, respectively, during the study phase. By contrast, in the intervention arm, there was a systematic reduction in MNSHE that was both statistically and clinically significant (Supplementary Fig. S2).

Because measurement of hypoglycemic events, as used in the SMILE study, is not readily available with currently available commercial CGM systems, we modeled the different factors excluding baseline MNSHE in Model 2. Among more accessible CGM-derived factors, only the baseline time spent below 54 mg/dL was found to be a significant and independent predictor (P < 0.0001; Supplementary Table S2). This factor explained 85.1% of the variability in MNSHE reduction in relation to baseline MNSHE. Lastly, when assessing all clinical and demographic factors available at baseline, excluding CGM-derived data (Model 3), HbA1c, mean SMBG, and CV of SMBG were statistically significant predictors, but their cumulative contribution to the variability of hypoglycemic episode reduction was smaller (38.7%).

From a clinical perspective, these findings suggest that baseline MNSHE is the strongest predictor of hypoglycemia reduction, and it should be considered an important metric; time below 54 mg/dL can be used when MNSHE is not readily available. Without CGM data, baseline HbA1c, mean SMBG, and CV of SMBG have a poor predictive value (38.7%). Therefore, CGM data are required to identify responders to therapy.

Interestingly, in the present analysis, age, gender, and body mass index were not associated with hypoglycemia reduction. Similarly, weight-corrected total daily insulin dose and total daily bolus dose were associated with hypoglycemia reduction on univariate analysis, whereas the type of insulin and the mean number of boluses per day were not. The Clarke score was also not predictive of hypoglycemia reduction: This may be because the included participants were hypoglycemia unaware, as defined by a Clarke score of ≥24 or Gold score ≥24, and hence little variability in Clarke score would be anticipated in this population.

The definition of a hypoglycemic episode as a sensor glucose below 54 mg/dL followed guideline recommendations, and the duration of ≥20 consecutive minutes has been used in previous studies. Because the Guardian Sensor 3 reports the glucose value every 5 min, a hypoglycemic event consists of at least four sensor glucose measurements, and hence can be considered a true episode of hypoglycemia. The SMILE study provided additional validity to this definition, by demonstrating a reduction in severe hypoglycemic events, which are clinical entities with clinical implications. By contrast, the recent consensus defining hypoglycemia as a minimum 15-min interval without consideration of sampling number is not evidence based.

A strength of this analysis is that the data were collected from a robust, prospective study, across a number of sites and countries, with a relatively long follow-up, which provided evidence of significant reductions of severe hypoglycemia in the intervention arm. Potential limitations are the post hoc nature of the analysis, and the fact that results are applicable only to the SMILE study population of people with type 1 diabetes and high risk of hypoglycemia, and hence the findings may not be generalizable to the wider diabetic population. In addition, the analysis used only 6 weeks of data, rather than the data from the full 6-month study. This approach was adopted for consistency with the main publication results, and to allow comparison with the regression seen during the three CGM periods in the control arm.

In conclusion, this analysis shows that the significant reduction of sensor hypoglycemic events demonstrated in the SMILE study with the MiniMed 640G system with the Suspend before low feature is strongly associated with the baseline MNSHEs. Measuring these events with CGM can serve as an important tool to predict hypoglycemia reduction, and for appropriate therapy selection. If this measurement is not available, time spent in hypoglycemia could be a valuable alternative, which is easier to implement in clinical practice.

Acknowledgments

The following investigational centers participated in the SMILE study: The number of patients randomized at each center is indicated in parentheses. Personnel are identified as investigators (I) and study coordinators (C). Ospedale S. Raffaele, Milan, Italy (17): Emanuele Bosi (I), Andrea Laurenzi (I), and Amelia Caretto (I). King’s College London, London, United Kingdom (14): Pratik Choudhary (I), David Slatterly (I), and Marcia Henderson-Wilson (C). Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada (13): S. John Weisnagel (I), Marie-Christine Dubé (C), and Valérie-Ève Julien (C). Ospedale Papa Giovanni XXIII, Bergamo, Italy (12): Roberto Trevisan (I), Giuseppe Lepore (I), and Rosalia Bellante (I). St. Joseph’s Health Care, London, Ontario, Canada (11): Irene Hramiak (I), Tamara Spaic (I), and Marsha Driscoll (C). Centre Hospitalier Universitaire de Besançon, Besançon, France (10): Sophie Borot (I), Annie Clergeot (I), and Lamia Khiat (C). Harrogate District Hospital, Harrogate, United Kingdom (10): Peter Hammond (I), Sutapa Ray (I), and Laura Dinning (C). Ospedale S. Giovanni di Dio, Olbia, Italy (10): Giancarlo Tonolo (I), Alberto Manconi (I), and Maura Serena Ledda (C). University Medical Center, Utrecht, The Netherlands (9): Harold de Valk (I), Wendela de Ranitz (I), and Bianca Silvius (C). Hôpital Lapeyronie, Centre Hospitalier Universitaire de Montpellier, France (8): Anne Wojtusyczyn (I) and Anne Farret (I). Isala Klinieken, Zwolle, The Netherlands (8): Titia Vriesendorp (I) and Folkje Immekeren-de Jong (C). Maasstadziekenhuis, Rotterdam, The Netherlands (7): Joke van der Linden (I), Huguetta S. Brink (I), and Marije Alkemade (C). Assistance Publique Hopitaux de Marseille—La Conception, Marseille, France (6): Pauline Schaepelynck—Belicar (I), Sébastien Galie (I), and Clémence Trégla (I). Centre Hospitalier Universitaire de
Grenoble, France (6): Sandrine Lablanche (I), Pierre-Yves Benhamou (I), and Myriam Haddouche (C). Groene Hart Ziekenhuis, Gouda, The Netherlands (6): Roel Hoogma (I). Manchester Diabetes Centre, Manchester, United Kingdom (6): Lalantha Leelarathna (I), Angel Shaju (C), and Linda James (C). Medical writing and editorial support in the preparation of this article was provided by Dr Michael Shaw (MScript Ltd., Hove, United Kingdom), and it was funded by Medtronic International Trading Sàrl, Tolochenaz, Switzerland.

Author Disclosure Statement

The principal investigators at each study center received research support and compensation from Medtronic International Trading Sàrl (Tolochenaz, Switzerland) and Medtronic Canada (Brampton, Canada) to conduct the study and collect data. A.H., J.C., S.d.P., J.D.S., L.V.-d.G., J.S., and O.C. are employees of Medtronic. E.B. reports nonfinancial support from Medtronic and consulting fees from Abbott and Roche. P.C. reports consulting fees and speaker honoraria from Medtronic; consultant fees from Dexcom, Roche Diabetes Care, Novo Nordisk, Sanofi Diabetes, Lilly Diabetes, Novartis, Ascencia Diabetes, andInsulet; and committee membership of the Diabetes Technology Network in the United Kingdom, which uses unrestricted sponsorship from industry partners to deliver educational programs for health care professionals. H.W.d.V. reports consulting fees from Medtronic. S.L. reports consulting fees from Medtronic. A.H. reports personal fees for salary, J.C. reports personal fees for salary and stock from Medtronic. S.d.P. reports personal fees for salary and stock from Medtronic. L.V.-d.G. reports personal fees for stock and stock from Medtronic. J.S. reports personal fees for salary and stock from Medtronic. O.C. reports personal fees for salary and stock from Medtronic.

Funding Information

This study was funded by Medtronic (Medtronic International Trading Sàrl [Tolochenaz, Switzerland] and Medtronic Canada [Brampton, ON, Canada]).

Supplementary Material

Supplementary Figure S1
Supplementary Figure S2
Supplementary Table S1
Supplementary Table S2
Supplementary Table S3
Supplementary Table S4

References

1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al.: Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307–1316.
2. Lachin JM, Orchard TJ, Nathan DM, et al.: Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:39–43.
3. Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, et al.: Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45–53.
4. Geddes J, Schopman JE, Zammitt NN, et al.: Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008;25:501–504.
5. Weinstock RS, Xing D, Maahs DM, et al.: Severe hypoglycaemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411–3419.
6. De Valk HW, Lablanche S, Bosi E, et al.: Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): design of a hypoglycaemia prevention trial with continuous glucose monitoring data as outcomes. Diabetes Technol Ther 2018;20:758–766.
7. Bosi E, Choudhary P, de Valk HW, et al.: Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:462–472.
8. Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774.
9. Davies MJ, D’Alessio DA, Fradkin J, et al.: Management of hyperglycaemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701.
10. International Hypoglycaemia Study Group: Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017;40:155–157.
11. Bergenstal RM, Klonoff DC, Garg SK, et al.: Threshold-based insulin-pump interruption for reduction of hypoglycaemia. N Engl J Med 2013;369:224–232.
12. Battelino T, Danne T, Bergenstal RM, et al.: Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42:1593–1603.

Address correspondence to:
Ohad Cohen, MD
Medtronic International Trading Sàrl
Route du Molliau 31
1131 Tolochenaz
Switzerland
E-mail: ohad.cohen@medtronic.com